Introduction
Trimeris is a biopharmaceutical company having the credit of successfully developing first fusion inhibitor: FUZEON, representing the first new class of anti-HIV treatments in seven years. As a part of its strategic initiatives in 2008, the company plans to: focus tightly on maximizing FUZEON's profitability by utilizing the resources and strengths of its collaborator, Roche.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Trimeris is primarily engaged in the discovery, development and commercialization of a class of antiviral drug treatments called fusion inhibitors. FUZEON, indicated for treating HIV/AIDS, is the only marketed product of Trimeris developed in collaboration with Roche.The company's lead product candidate, TRI-1144 is in preclinical research. Trimeris derives its revenues as royalties from Roche based on total net sales of FUZEON outside the US and Canada and collaboration income on FUZEON sales in the US and Canada. The company develops products utilizing its own or combined research efforts of its collaborators. Trimeris did not record any revenues during 2002-2004. The company's total revenues increased from $19 million in 2005 to $37 million in 2006. The company's biggest contributor to revenue growth during 2005-2006 was collaboration income on FUZEON sales in the US and Canada.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
